PLRX

Conviction 0HealthcareScan · Mon, Aug 10, 2026

Hammer

PLRX$1.05-0.48%

ResistanceSupportVol 14

Vol MA14 379.42K

May 11May 28Jun 16Jul 6Jul 23Aug 10

PLIANT THERAPEUTICS, INC.PHARMACEUTICAL PREPARATIONSwww.pliantrx.com ↗

Price1.05

Change-0.48%

Gap+0.00%

Rel volume0.40×

Avg volume534.76K

Avg $ vol579.27K

SMA 201.07

SMA 501.12

SMA 2001.28

Price vs 50-7.00%

Price vs 200-18.34%

MA stackbearish

50/200 cross—

Supertrenddown · 1.15

RSI (14)39

MACD hist0.00

MACD crossbull · 0d

Stoch %K / %D18 / 20

ADX (14)30

+DI / −DI7 / 17

RSI divergence—

MACD divergence—

ATR %+3.76%

ADR %3.83%

52w high1.87

52w low1.04

From 52w high-44.12%

Above 52w low+0.48%

New 52w highNo

SqueezeOn · 1d

Bollinger width10.84%

%B0.25

Donchian pos11.54%

Donchian high1.16

Donchian low1.03

AVWAP (52w high)1.30

vs AVWAP high-19.48%

AVWAP (52w low)1.05

vs AVWAP low-0.39%

OBV trendDown

Chaikin MF (20)-0.26

Today vs 20d0.40×

Avg vol (14d)379.42K

Avg vol (20d)534.76K

Avg $ vol (20d)579.27K

Market cap64.71M

RS 3m (vs SPY)-21.02%

RS 6m (vs SPY)-17.78%

RS line new highNo

Trend template0/8

Technical rank17.7

1 week+0.48%

1 month-6.70%

3 months-14.34%

6 months-8.33%

1 year-37.80%

YTD-16.40%

P/E-0.43

P/B0.39

P/S—

P/FCF-0.50

EPS-2.43

Div yield—

ROE-90.42%

ROA-73.72%

Debt/Eq0.00

Current16.89

EV/EBITDA—

Gross margin—

Net margin—

Rev growth—

EPS growth28.99%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value42.52M

Revenue0

Net income-20.04M

Gross profit—

Free cash flow-128.71M

IndustryPHARMACEUTICAL PREPARATIONS

ExchangeNasdaq

Shares out61.92M

Employees49

ListedWed, Jun 3, 2020

Free float48.35M

Float %78.7%

Short interest2.82M

Days to cover3.3d

Short volume34.8%

Squeeze score28 / 100

Next earnings—

EPS forecast—

Last EPS vs est−$0.32 vs −$0.36

Last surprise+11.1% beat

Setup gradeD

Conviction0 / 100

Pattern quality—

Tech rank17.7 / 100

Group rank86 / 100 · Leading

Status lane—

Setup direction—

Pattern family

Resistance—

Support—

Days since event—

Candle confirmHammer

News sentiment—

Financials as of Tue, Mar 31, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in PLRX

All disclosures →

No recent disclosed trades by Congress in PLRX. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in PLRX · 5 buys · 5 sells

Insider	Side	Shares	Value	Traded	Filed
Borellini Flavia Director · Stock Option (Right to Buy) · 2026-07-09	Grant	60K	—	2026-07-09	2026-07-13
Iannone Robert Director · Stock Option (Right to Buy) · 2026-07-09	Grant	60K	—	2026-07-09	2026-07-13
Coulie Bernard President and CEO · Stock Option (Right to Buy) · 2026-04-17	Grant	325K	$0	2026-04-17	2026-04-17
Coulie Bernard President and CEO · Stock Option (Right to Buy) · 2026-04-17	Disposition	440K	$0	2026-04-17	2026-04-17
Kuo Minnie Chief Operating Officer · Stock Option (Right to Buy) · 2026-04-17	Disposition	40K	$0	2026-04-17	2026-04-17
Coulie Bernard President and CEO · Stock Option (Right to Buy) · 2026-04-17	Disposition	256.3K	$0	2026-04-17	2026-04-17
Coulie Bernard President and CEO · Stock Option (Right to Buy) · 2026-04-17	Disposition	250K	$0	2026-04-17	2026-04-17
Cummings Keith Lamont Chief Financial Officer · Stock Option (Right to Buy) · 2026-04-17	Disposition	18.2K	$0	2026-04-17	2026-04-17
Cheung Lily Chief Human Resource Officer · Stock Option (Right to Buy) · 2026-04-17	Grant	51.75K	$0	2026-04-17	2026-04-17
Coulie Bernard President and CEO · Stock Option (Right to Buy) · 2026-04-17	Grant	206.3K	$0	2026-04-17	2026-04-17

SEC filings

EDGAR filings in PLRX · 2 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.